BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $4.07M rose 276.4% year over year, ahead of the +85.5% change in trailing-twelve-month other income / expenses. Sequentially, it fell 11.7% from the prior quarter.
Context
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +276.4% holds above the trailing-twelve-month pace of +85.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 11.78M USD
- Year-over-year change
- +43.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.78M | +43.9% |
| FY2024 | 2024-12-31 | 8.18M | +11266.5% |
| FY2023 | 2023-12-31 | 72K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Income / Expenses vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +85.5% is the 3rd highest of 10, against a peer median of -2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.23M USD | +206.4% | +46.5% | 52.6% | |
| LTM Sep 2026 | $20.48M USD | +106.3% | +48.7% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $20.33M USD | +12.8% | — | 21.1% |
| LTM Aug 2026 | $18.56M USD | -20.1% | +84.3% | 2.6% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $14.77M USD | +85.5% | — | — |
| LTM Sep 2026 | $4.41M USD | -23.7% | -16.4% | — | |
| LTM Mar 2026 | -CHF 10.98M CHF | +56.5% | — | 2178.2% | |
| LTM Mar 2026 | -$30.1M USD | -10.2% | — | 21.4% | |
| LTM Mar 2026 | -$60.7M USD | -2.2% | — | 29.6% | |
| LTM Mar 2026 | -$67.43M USD | -67.3% | — | 29.0% | |
| Peer median (excluding BBOT) | — | -2.2% | +47.6% | 29.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.